Research and Markets: OpportunityAnalyzer: Endometriosis - Elagolix Launch to Revive Declining Endometriosis Treatment Market by 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9nqgpq/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecasts to 2017" report to their offering.
“OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecasts to 2017”
The global endometriosis therapeutics market will experience a slow decline over the coming years, with revenue decreasing from $1.88 billion in 2012 to $1.66 billion by 2017, at a negative Compound Annual Growth Rate (CAGR) of 0.19%, says a new report from research and consulting firm The authors.
According to the company's latest report, this decline can be largely attributed to the patent expiry of Lupron (leuprolide acetate) in 2014.
However, the waning market will regain momentum following the expected launch of elagolix in the US and five European countries - France, Germany, Italy, Spain and the UK - in 2016. Elagolix is one of the first-in-class, oral gonadotropin-releasing hormone (GnRH) antagonists currently dominating the late-stage pipeline for endometriosis therapeutics. The authors believes that these treatments will rapidly replace the GnRH agonist market segment.
Anita Angelica Moore, The authors's Analyst covering Oncology and Women's Health, says: "Key opinion leaders believe that an oral formulation will be a welcome addition to the field, as it will provide doctors with increased control over dosing and allow for the immediate cessation of therapy, if necessary. In comparison with GnRH agonists, such as Lupron and Zoladex, these drugs also lead to fewer hypoestrogenic side effects."
Based on their improved efficacy and safety profiles, elagolix and other GnRH antagonists are likely to be priced at a premium over GnRH agonists. As pricing is a key influence behind therapy choice in the endometriosis market, The authors says that these new treatments will have little potential to steal shares from low-cost therapies, including combined oral contraceptives, non-steroidal anti-inflammatory drugs and progestins.
Despite the expected launch of elagolix, significant unmet needs remain in the endometriosis market, due to the current lack of approved treatment options that boast continuous efficacy and favorable long-term safety profiles.
Moore concludes: "As the methods of treating this condition have proven largely haphazard, women often undergo numerous rounds of surgery and try several medical approaches before finding relief. Even then, they can expect a high rate of recurrence. Ultimately, since none of the drugs on the horizon are curative, opportunity remains for innovative therapies that target the root cause of the condition."
This report provides an overview of endometriosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis and treatment guidelines. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the endometriosis therapeutics market.
Key Topics Covered:
List of Tables
List of Figures
Current Treatment Options
Unmet Needs Assessment and Opportunity Analysis
Pipeline Valuation Analysis
List of Tables
List of Figures
For more information visit http://www.researchandmarkets.com/research/9nqgpq/opportunityanalyze
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.